At the time of writing, Roivant Sciences Ltd [ROIV] stock is trading at $12.57, down -0.16%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ROIV shares have gain 4.84% over the last week, with a monthly amount glided 8.08%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Roivant Sciences Ltd [NASDAQ: ROIV] stock has seen the most recent analyst activity on September 02, 2025, when Citigroup initiated its Buy rating and assigned the stock a price target of $16. On February 15, 2024, Wolfe Research initiated with a Outperform rating and assigned a price target of $17 on the stock. Piper Sandler started tracking the stock assigning a Overweight rating and suggested a price target of $20 on January 05, 2024. Deutsche Bank initiated its recommendation with a Buy and recommended $14 as its price target on December 12, 2023. Guggenheim started tracking with a Buy rating for this stock on October 17, 2023, and assigned it a price target of $17. In a note dated June 08, 2023, BofA Securities initiated a Neutral rating and provided a target price of $10.50 on this stock.
For the past year, the stock price of Roivant Sciences Ltd fluctuated between $8.73 and $13.06. Currently, Wall Street analysts expect the stock to reach $16.21 within the next 12 months. Roivant Sciences Ltd [NASDAQ: ROIV] shares were valued at $12.57 at the most recent close of the market. An investor can expect a potential return of 28.96% based on the average ROIV price forecast.
Analyzing the ROIV fundamentals
According to Roivant Sciences Ltd [NASDAQ:ROIV], the company’s sales were 23.23M for trailing twelve months, which represents an -96.06% plunge. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -51.05%, Pretax Profit Margin comes in at -40.08%, and Net Profit Margin reading is -21.12%. To continue investigating profitability, this company’s Return on Assets is posted at -0.1, Equity is -0.1 and Total Capital is -0.24. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 12.37 points at the first support level, and at 12.18 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.92, and for the 2nd resistance point, it is at 13.28.
Ratios To Look Out For
It is important to note that Roivant Sciences Ltd [NASDAQ:ROIV] has a current ratio of 40.54. As well, the Quick Ratio is 40.54, while the Cash Ratio is 10.88. Considering the valuation of this stock, the price to sales ratio is 369.51, the price to book ratio is 1.97.
Transactions by insiders
Recent insider trading involved Venker Eric, President & Immunovant CEO, that happened on Aug 20 ’25 when 100000.0 shares were sold. Officer, Venker Eric completed a deal on Aug 20 ’25 to buy 100000.0 shares. Meanwhile, President & Immunovant CEO Venker Eric sold 100000.0 shares on Jul 21 ’25.
